Since 2015, Anti-PD1/PD-L1 immunotherapy has become the standard treatment for stage III-IV NSCLC patients with satisfactory expressions of PD1/PD-L1 [19]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.